Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Poseida Therapeutics, Inc. | pstx-ex321_7.htm |
| EX-31.2 - EX-31.2 - Poseida Therapeutics, Inc. | pstx-ex312_8.htm |
| EX-31.1 - EX-31.1 - Poseida Therapeutics, Inc. | pstx-ex311_9.htm |
| EX-23.1 - EX-23.1 - Poseida Therapeutics, Inc. | pstx-ex231_845.htm |
| EX-21.1 - EX-21.1 - Poseida Therapeutics, Inc. | pstx-ex211_718.htm |
| EX-4.6 - EX-4.6 - Poseida Therapeutics, Inc. | pstx-ex46_717.htm |
| 10-K - 10-K - Poseida Therapeutics, Inc. | pstx-10k_20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Poseida Therapeutics, Inc. (the “Company”) for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I hereby certify to the best of my knowledge, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 11, 2021 |
|
By: |
/s/ Mark J. Gergen |
|
|
|
|
Mark J. Gergen, J.D. |
|
|
|
|
President, Chief Business Officer (Principal Financial Officer) |
This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.